Vries, S.H. de

Active Surveillance and Prostate Cancer Screening (Doctoral Thesis)

2009-12-02T00:00:00Z

The aim of this thesis is to contribute to the evaluation of active surveillance as an option for selected men with adenocarcinoma of the prostate. Active surveillance (AS) entails an active observation policy for men with presumably curable prostate cancer (PCa) at diagnosis. The concept of AS is to avoid unnecessary treatment, with its inherent side effects and costs, while preserving the window of cure with active surveillance, in these males with PCa. Though it sounds and even feels contradictory to delay treatment in a PCa patient, the rationale of AS can be explained by several convincing arguments.

hK2 and Free PSA, a Prognostic Combination in Predicting Minimal Prostate Cancer in Screen-Detected Men within the PSA Range 4-10 ng/ml (Article)

2007-11-01T00:00:00Z

Objectives: The purpose of screening for prostate cancer is to decrease the disease-specific mortality. However not every screen-detected prostate cancer is a threat to the patient's life. The risk of overdetection and subsequent overtreatment in prostate cancer has been recognised. The purpose of this investigation was to evaluate the role of tumour markers total PSA, free PSA, and hK2, and their combinations in predicting minimal prostate cancer. Methods: Within the European Randomized Study of Screening for Prostate Cancer (ERSPC), section Rotterdam, The Netherlands, prebiopsy serum samples were analysed for 100 selected men who underwent a radical prostatectomy for their screen-detected prostate cancer. All had a PSA value between 4 and 10 ng/ml prior to diagnosis. Minimal prostate cancer is defined as organ confined, Gleason score ≤6 (no Gleason grade 4 or 5), and tumour volume <0.5 ml. Results: Sera and tumour volumes from 91 men were available for analysis. Minimal prostate cancer was diagnosed in 16.5% of the selected cases. Mean tumour volume was 1.2 ml (range: 0.04-13.5); hK2, the algorithms hK2/fPSA, and hK2/%fPSA have significant correlations with tumour volume. Both algorithms also yielded the best test results in predicting minimal disease with an area under the receiver operator characteristics curve of 82%. Conclusions: hK2 and percent free PSA have added prognostic value for the detection of minimal prostate cancer in screen-detected cases within PSA range 4-10 ng/ml. These biomarkers can possibly be used to select less invasive treatment options like active surveillance and to prevent overtreatment.

Active Surveillance for Prostate Cancers Detected in Three Subsequent Rounds of a Screening Trial: Characteristics, PSA Doubling Times, and Outcome (Article)

2007-05-01T00:00:00Z

Objectives: To study active surveillance as a management option for the important number of prostate cancer patients who would not have been diagnosed in the absence of screening. Patients and methods: We analyzed baseline characteristics and outcome parameters of all men on active surveillance who were screen-detected in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Recruitment and surveillance of men were not guided by a protocol but depended on individual decisions of patients and their physicians. Results: Active surveillance was applied in 278 men detected by screening from 1993 to 2006. At diagnosis, their median age was 69.8 yr (25-75p; 66.1-72.8); median PSA 3.6 ng/ml (25-75p; 3.1-4.8), and the clinical stage was T1c in 220 (79.1%) and T2 in 58 (20.9%). During the follow-up of median 3.4 yr, 103 men (44.2%) had a PSA doubling time that was negative (ie, half-life) or longer than 10 yr. Men detected at rescreening were significantly more likely to be on active surveillance, and they had more beneficial characteristics. Deferred treatment was elected in 82 cases (29.0%). Overall survival was 89% after 8 yr; the cause-specific survival was 100%. Conclusions: This report shows a beneficial, although preliminary, outcome of screen-detected men managed on active surveillance. Men were more likely to be on active surveillance if the disease was detected at repeated screening. The report also shows that an important proportion of men have prolonged PSA doubling times, although the value of this parameter has not been established in untreated men.

Overall and Disease-Specific Survival of Patients with Screen-Detected Prostate Cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam (Article)

2007-02-01T00:00:00Z

Introduction: This report describes survival data of participants of the European Randomized Study of Screening for Prostate Cancer (ERSPC), section Rotterdam, diagnosed with prostate cancer (pCA) during the first round of screening, the prevalence screen. Patients and methods: pCA characteristics from cases diagnosed during the first screening round from December 1993 to March 2000 are shown. During follow-up, data were collected by semiannual patient chart review for the first 5 yr and annually thereafter. The causes of death are scored according to the diagnosis of the treating physician and are not based on the review of the independent causes-of-death committee. Overall and disease-specific survival graphs are shown in Kaplan-Maier projections and compared with expected survival outcomes for males in the same age categories from the Dutch provinces of North Holland and Flevoland. Statistical evaluation was based on Cox regression analysis. Results: During the prevalence screening, 1014 patients were diagnosed with pCA. Median follow up was 55 mo, 126 (12.4%) patients died, 20 (2.0%) of pCA. Overall 5-yr observed and expected disease-specific survival was 97.7% and 82%, respectively. In the multivariate analysis, a Gleason sum of 4+4 or higher (p = 0.025) was predictive of pCA death. Conclusions: The observed survival data are in line with the literature and the expected favorable outcome for a screened population. The proportion of men dying from pCA is still small, and a 10-yr follow-up period for the final evaluation of the ERSPC may be too short.

Prostate volume ultrasonography: the influence of transabdominal versus transrectal approach, device type and operator (Article)

2004-08-13T00:00:00Z

OBJECTIVES: We conduct a longitudinal non-invasive study of changes in urinary bladder contractility secondary to benign prostatic enlargement. In that study, the prostate volume is estimated by transabdominal ultrasonography. The accuracy of those measurements was verified by comparison of transabdominal to transrectal stepwise planimetric ultrasonography as the gold standard. Also, two different transabdominal devices used were compared, and the influence of different operators was studied. MATERIALS & METHODS: Two series of measurements in 100 patients each were done. In the first series, transabdominal and transrectal sonography were pairwise compared in each patient. In the second series, transabdominal measurements were done with two devices (a hospital Aloka SSD-1700 and a portable Aloka SSD-900). Transrectal scannings were done by three investigators whilst all transabdominal scannings were done by one. Regression graphs, ratio plots and statistical analyses of the data quantified the reproducibility of different methods, observers and device types. RESULTS: In the transrectal-transabdominal series of prostate volume measurements (in cm3), the Pearson correlation coefficient was 0.84 (p < 0.001), the mean of the means was 51.8 +/- 23.0 (mean +/- S.D.), and the mean of the differences was 1.0 +/- 1.4. In the series with two devices, the Pearson correlation coefficient was 0.73 (p < 0.001), the mean of the means was 31.0 +/- 10.9, and the mean of the differences was 1.0 +/- 1.3. CONCLUSION: No statistically significant differences were found between the transabdominal- transrectal ultrasonography, two different transabdominal devices nor between different observers. However, for those using these measurements in everyday clinical practice, it is worth to point out that in our data a transabdominal scan and a transrectal scan in the same patient, on the same day, differed more than 30% in one fourth of the patients and that two transabdominal scans in the same patient (with two different devices, on two different days) differed more than 30% in every fifth patient